Change to Board of Directors
LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that Erich Spangenberg, Non-Executive Director, has elected to resign as a director of the Company effective October 31st2022.
Mr. Spangenberg commented: “I was the first outside investor in Spectral MD in 2011 and have served on the Board of Directors for over 10 years. I am the CEO of two other businesses that are now at a point in their development where they simply demand all my available business time. Today, my family is the largest shareholder in Spectral MD and my plan is to continue to support the Company, management and the Board of Directors. Wensheng is an exceptional CEO and I strongly believe that under his guidance great things lie ahead for Spectral MD.”
Wensheng Fan, Spectral MD Chief Executive Officer, said: “Erich has consistently brought tremendous insights to our Company through his extensive experience and broad industry knowledge in technology, finance, IP and governance. Erich has been, and I am sure will continue to be a strong supporter of Spectral MD. On behalf of the entire Spectral MD team, I would like to thank Erich for his commitment and contributions to the Company.”
Martin Mellish, Chairman of the Board, commented: “On behalf of the Board and the Company, I would like to thank Erich for his exceptional service on the Board of Spectral MD over the years as the Company’s largest shareholder and supporter. The Board is finalising its evaluation of the appropriate skill set and profile of a replacement Non-Executive Director on the Board as we progress to the next stage of the Company’s development, and we look forward to initiating a selection process.”
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (‘MAR’). Upon the publication of this announcement via Regulatory Information Service (‘RIS’), this inside information is now considered to be in the public domain.
For further information please contact:
| Spectral MD Holdings, Ltd. | investors.spectralmd.com |
| Wensheng Fan, Chief Executive Officer | via Walbrook PR |
| Nils Windler, Chief Financial Officer | |
| SP Angel Corporate Finance LLP (NOMAD and Joint Broker) | Tel: +44 (0)20 3470 0470 |
| Stuart Gledhill/Caroline Rowe (Corporate Finance)Vadim Alexandre/Rob Rees (Sales & Broking) Stifel Nicolaus Europe Limited (Joint Broker)Charles Hoare / Ben Maddison / Nick Harland /Will Palmer-Brown | Tel: +44 (0)20 7710 7600 |
| Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com |
| Paul McManus / Louis Ashe-Jepson Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393 +44 (0)7407 804 654 |
About Spectral MD:
We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by “Seeing the Unknown” ® with our DeepView® Wound Imaging System.